An interventional study of 27-Inch Endoscopic Imaging Monitor and 55-Inch Endoscopic Imaging Monitor in Endometrial Cancer, sponsored by Metehan Uzundal. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Metehan Uzundal · Not applicable, Interventional, and Other
This study will compare the use of 27-inch and 55-inch endoscopic imaging monitors during minimally invasive surgery for women with endometrial cancer. Participants will be randomly assigned to one of the two monitor groups. All participants will undergo the same standard surgical procedure; only the monitor size used during surgery will differ. The main question is whether monitor size affects total operative time. The study will also evaluate sentinel lymph node dissection time, blood count changes, complications, infections, hospital stay, and drain-related outcomes during the first 30 days after surgery.
This is a single-center, prospective, randomized, parallel-group clinical study designed to evaluate whether endoscopic imaging monitor size affects surgical and early postoperative outcomes in minimally invasive endometrial cancer surgery. Eligible adult women with histologically diagnosed endometrial cancer who are scheduled for total laparoscopic hysterectomy with bilateral salpingectomy or salpingo-oophorectomy and bilateral sentinel lymph node dissection will be enrolled after informed consent.
Participants will be randomly assigned in a 1:1 ratio to surgery using either a 27-inch endoscopic imaging monitor or a 55-inch endoscopic imaging monitor. Both monitor systems are standard surgical imaging equipment used in routine clinical practice. The surgical procedure, operative technique, energy devices, sentinel lymph node mapping approach, and postoperative care will be standardized across both groups. No additional invasive procedure, investigational drug, biologic product, or experimental treatment will be used as part of this study.
The primary outcome measure is total operative time, defined as the time from entry of the laparoscopic optic into the abdomen after trocar placement to completion of surgery. Secondary outcomes include bilateral pelvic sentinel lymph node dissection time, number of right and left sentinel lymph nodes removed, hemoglobin and hematocrit decrease, blood transfusion requirement, intraoperative complications, postoperative complications within 30 days, postoperative infections within 30 days, Clavien-Dindo complication grade, length of hospital stay, drain requirement, and postoperative day of drain removal if a drain is placed.
Participants will be followed during hospitalization and at postoperative day 7-10 and day 30 visits. The study aims to determine whether monitor size has a measurable effect on operative performance and early postoperative outcomes in a standardized minimally invasive surgical setting.
1,347 studies on the registry are indexed under Endometrial Neoplasms; 452 are open to participants now.
This study's planned enrollment of 70 is close to the median of 70 across 954 interventional studies indexed under Endometrial Neoplasms.
Browse Endometrial Neoplasms studies →This is the only study on the registry with Metehan Uzundal as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomized to this arm will undergo minimally invasive endometrial cancer surgery using a 27-inch 4K-2D endoscopic imaging monitor. The surgical procedure and perioperative care will be standardized.
Device: 27-Inch Endoscopic Imaging Monitor
Participants randomized to this arm will undergo the same minimally invasive endometrial cancer surgery using a 55-inch 4K-2D endoscopic imaging monitor. The surgical procedure and perioperative care will be standardized.
Device: 55-Inch Endoscopic Imaging Monitor
Use of a 27-inch 4K-2D endoscopic imaging monitor during minimally invasive endometrial cancer surgery.
Use of a 55-inch 4K-2D endoscopic imaging monitor during minimally invasive endometrial cancer surgery.
Total Operative Time
Total operative time, defined as the time from entry of the laparoscopic optic into the abdomen after trocar placement to completion of surgery, measured in minutes.
Time frame: During surgery
Bilateral Pelvic Sentinel Lymph Node Dissection Time
Time required to complete bilateral pelvic sentinel lymph node dissection, measured in minutes.
Time frame: During surgery
Number of Retrieved Sentinel Lymph Nodes
Number of right and left sentinel lymph nodes removed during surgery.
Time frame: From surgery to final pathology assessment, up to 30 days after surgery
Hemoglobin Decrease
Percentage decrease in hemoglobin level calculated using preoperative and postoperative 24-hour hemoglobin values.
Time frame: Preoperative to postoperative 24 hours
Hematocrit Decrease
Percentage decrease in hematocrit level calculated using preoperative and postoperative 24-hour hematocrit values.
Time frame: Preoperative to postoperative 24 hours
Blood Transfusion Requirement
Need for perioperative or postoperative blood transfusion, recorded as yes or no.
Time frame: From start of surgery to hospital discharge, up to 30 days after surgery
Intraoperative Complications
Occurrence of any intraoperative complication, recorded as yes or no.
Time frame: During surgery
Postoperative Complications Within 30 Days
Occurrence of any postoperative complication within 30 days after surgery, recorded as yes or no.
Time frame: Up to 30 days after surgery
Postoperative Infections Within 30 Days
Occurrence of postoperative infection within 30 days after surgery, recorded as yes or no.
Time frame: Up to 30 days after surgery
Clavien-Dindo Complication Grade
Severity of postoperative complications classified according to the Clavien-Dindo classification
Time frame: Up to 30 days after surgery
Length of Hospital Stay
Duration of postoperative hospital stay, measured in days.
Time frame: From surgery to hospital discharge, up to 30 days after surgery
Drain Requirement
Need for postoperative drain placement, recorded as yes or no.
Time frame: From surgery to hospital discharge, up to 30 days after surgery
Postoperative Day of Drain Removal
Postoperative day on which the drain is removed in participants with a drain placed
Time frame: From surgery to drain removal, up to 30 days after surgery
Plan to share: No — Individual participant data will not be shared. Study data will be collected and analyzed in a coded and confidential manner, and participant-identifying information will not be disclosed. Results will be reported only in aggregate form.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.